| Literature DB >> 34168377 |
Elisabeth C Inwald1, Christian Albring2, Erika Baum3, Maria Beckermann4, Kai J Bühling5, Günter Emons6, Thomas Gudermann7, Peyman Hadji8, Bruno Imthurn9, Ludwig Kiesel10, David Klemperer11, Petra Klose12, Klaus König13, Stephanie Krüger14, Jost Langhorst15, Michael Leitzmann16, Albert Ludolph17, Diana Lüftner18, Dorothea Müller19, Joseph Neulen20, Monika Nothacker21, Horst Prautzsch22, Vera Regitz-Zagrosek23, Kathrin Schaudig24, Florian Schütz25, Anneliese Schwenkhagen24, Thomas Strowitzki26, Petra Stute27, Bettina-Maria Taute28, Clemens Tempfer29, Christine V Arnim30, Ludwig Wildt31, Eberhard Windler32, Olaf Ortmann1.
Abstract
Aim The aim of the interdisciplinary S3-guideline Perimenopause and Postmenopause - Diagnosis and Interventions is to provide help to physicians as they inform women about the physiological changes which occur at this stage of life and the treatment options. The guideline should serve as a basis for decisions taken during routine medical care. This short version lists the statements and recommendations given in the long version of the guideline together with the evidence levels, the level of recommendation, and the strength of consensus. Methods The statements and recommendations are largely based on methodologically high-quality publications. The literature was evaluated by experts and mandate holders using evidence-based medicine (EbM) criteria. The search for evidence was carried out by the Essen Research Institute for Medical Management (EsFoMed). To some extent, this guideline also draws on an evaluation of the evidence used in the NICE guideline on Menopause and the S3-guidelines of the AWMF and has adapted parts of these guidelines. Recommendations Recommendations are given for the following subjects: diagnosis and therapeutic interventions for perimenopausal and postmenopausal women, urogynecology, cardiovascular disease, osteoporosis, dementia, depression, mood swings, hormone therapy and cancer risk, as well as primary ovarian insufficiency. Thieme. All rights reserved.Entities:
Keywords: cancer risk; diagnosis; guideline; hormone (replacement) therapy; perimenopause; postmenopause; therapy
Year: 2021 PMID: 34168377 PMCID: PMC8216766 DOI: 10.1055/a-1361-1948
Source DB: PubMed Journal: Geburtshilfe Frauenheilkd ISSN: 0016-5751 Impact factor: 2.915